Member Info for Laura2022

Looking brilliant

You can't help yourself can you?

Says the person plaguing VAL for 2yrs

Cashflow

The Company has to date received the 1st US$500,000 from Cynergy and once the conditions precedent have been satisfied, it will transfer the second tranche. This, combined with the fact that no cash flow is being generated at Kilimapesa, has placed the Company under significant cash flow pressure and distress. The Company is engaged with various stakeholders to raise the required funding to ameliorate this situation and will provide updates in due cours

And Kick the can

Wonder who's benefiting from the £70k interest...I bet not anyone connected either Bell ...cough cough

The Company announces, further to the announcement of 7 August 2023, that the Note holders have agreed to extend the term and conversion rights of the Notes to 18 November 2024.

The total amount of Notes outstanding immediately following the term extension is £562,840, and accrued interest is £73,462. E

Morning Freddie

Doe this help VAL plz?

Porky not posted for 6 days now so I assume he's had yet another 7 day LSE bam for false and misleading posts

Activities including:

· Recruitment of a Head of Mathematical Modelling Service Line to accelerate conversion of the pipeline and drive operational excellence.

· Further investment in Business Development and Marketing to build and strengthen the pipeline, expand into new therapeutic areas, develop its data science offering and launch its biostatistics offering.

· Build a biostatistics capability, including team expansion, development of processes, acquisition of necessary tools and exploration of strategic options.

· Implementation of the personalised dosing tool on the DoseMeRx Platform, enabling it to be available to clinicians across the US and deliver on a study in partnership with DoseMeRx to further develop the tools H-CSF functionality.

Yes KingH and also we can then get some updates on the progress of initiatives mentioned in the placing RNS

The Board also wishes to advise that the Group continues to be in discussion with a small number of potential institutional lenders about entering into substantial longer term debt facilities that would allow the Committed Credit Facility to be refinanced.

Current Cash Position

The Company continues to manage its cash position and creditors tightly, and this has been exacerbated by the delay in receipt of monies from the Third Admission of equity proceeds and the £1m draw down from the Committed Credit Facility.

The Company's cash position as at 22 August 2024 is currently £210k. This sum is expected to increase once the remaining proceeds of the subscription and the funds due under the draw down are received. The Group's going concern is dependent on timely receipt of funds under the equity fundraise and the committed credit facility or alternative financing (which as yet have not been secured).

James Short, Chief Executive Officer of Celadon, commented:

"Celadon is grateful to the investor and lender for their re-confirmed commitments to the Company and for the additional funds received from the lender.

"The Group's ongoing conversations with alternative potential lenders continue to progress positively with a view to securing the long-term future for the business."

July 11, 2024 – Johnson & Johnson1 (NYSE: JNJ) announced today that it has successfully completed the acquisition of Yellow Jersey, a demerged subsidiary of Numab Therapeutics to secure the global rights to NM26, a novel, investigational first-in-class bispecific antibody, in an all-cash transaction of approximately $1.25 billion, as announced on May 28, 2024.

Now that would be interesting...inthink KingH or Debull posted something about Numab a few weeks ago ?

I had a reply ( as did one other?) A few weeks ago that due to the quietness of the summer the presentation would be better early September

Therefore I assume this will be via IMC and confirmed shortly

Have you tried emailing/contacting ?

I have always has a reply

It's the regularity

And 20% of enlarged shares

Incredible

Will take a look

Commenting Paul Pagano, Chief Executive Officer of LungLife, said:

"The successful clinical validation of the LungLB® test and other achievements in this period reflect our commitment to advancing early detection of lung cancer and the team remains dedicated to making a significant impact in this critical area of healthcare.

We are delighted with the increasing recognition for LungLB® as evidenced by the positive clinician feedback together with the first orders being received under our Early Access Program. Whilst we progress towards commercialisation, we are also actively seeking opportunities for a suitable strategic partner who aligns with our vision and has the capability to accelerate the adoption of LungLB®."

 

Hello Mike

I agree here

In my view LLAI and PYC are the best 2.A.I medical stocks on the market in the Uk

I have purchased more today

Worth clicking on the posts from Kinghomer, Debull and Trench123

From KingHomer

This is severely undervalued at current MC.

Even at 2p (4 Million MC) its still a steal....lots of news to come to build from here.

* Highest Level of Revenue going into financial year £600k (We are 2 months into it)

* Dosemerx update & Collab

* NHS Prostate Cancer Trial ongoing - update due

* Beyond Blood Trial ongoing - update due (i would suggest people look at the shareholders on this one) Companies House

* Bicycle Therapeutics Update due - to be announced in September

* New Revenue Arm launched

* New Recruit has moved from AstraZeneca

* VAL 201 (Up to £6mil) if that ever ever ever happens who knows....